OverviewSuggest Edit

Precision BioSciences is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions.

TypePublic
Founded2006
Websiteprecisionbiosciences.com
Employee Ratings4.9

Latest Updates

Employees (est.) (Dec 2019)199(+9%)
Job Openings15
Revenue (FY, 2020)$24.3 M(-97%)
Share Price (Dec 2021)$7.4(-2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Precision BioSciences

Kevin Buehler

Kevin Buehler

Chairman
Cindy Atwell

Cindy Atwell

Vice President, Business Development
Dario Scimeca

Dario Scimeca

General Counsel
Derek Jantz

Derek Jantz

Director, Chief Scientific Officer, Co-Founder
Jeff Smith

Jeff Smith

Chief Technology Officer, Co-Founder
Abid Ansari

Abid Ansari

Chief Financial Officer
Show more

Precision BioSciences Office Locations

Precision BioSciences has an office in Durham
Durham, NC, US
302 E Pettigrew St
Show all (1)

Precision BioSciences Financials and Metrics

Precision BioSciences Revenue

Precision BioSciences's revenue was reported to be $24.29 m in FY, 2020
USD

Revenue (Q1, 2021)

16.3m

Net income (Q1, 2021)

(18.7m)

EBIT (Q1, 2021)

(18.7m)

Market capitalization (31-Dec-2021)

460.9m

Closing stock price (31-Dec-2021)

7.4

Cash (31-Mar-2021)

193.5m

EV

277.5m
Precision BioSciences's current market capitalization is $460.9 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

6.5m10.9m1.1b24.3m

Revenue growth, %

68%

General and administrative expense

8.0m13.7m27.0m36.1m

R&D expense

20.3m45.1m82.4m98.1m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

5.5m5.4m4.9m7.0m1.1m16.3m

General and administrative expense

5.0m6.5m7.1m9.6m8.7m9.5m

R&D expense

20.0m22.8m19.8m24.9m25.2m25.6m

Operating expense total

25.0m29.3m26.8m34.5m33.9m35.1m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

62.8m103.2m180.9m89.8m

Accounts Receivable

523.0k965.0k10.0m

Prepaid Expenses

1.4m8.9m9.5m5.8m

Current Assets

64.3m115.7m193.7m105.6m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

116.5m226.1m206.3m154.2m126.9m193.5m

Accounts Receivable

6.2m250.0k250.0k3.9m83.0k19.3m

Prepaid Expenses

10.7m7.9m10.2m6.4m

Current Assets

137.0m237.1m219.5m166.8m137.4m219.1m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(21.1m)(46.0m)(92.9m)(109.0m)

Depreciation and Amortization

1.4m2.4m5.3m8.8m

Accounts Payable

864.0k(673.0k)667.0k(1.5m)

Cash From Operating Activities

(24.2m)(51.7m)(71.0m)(87.4m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(31.8m)(51.2m)(72.0m)(26.8m)(59.5m)(18.7m)

Depreciation and Amortization

939.0k2.1m3.5m2.2m4.4m2.2m

Accounts Payable

1.5m207.0k597.0k(266.0k)(121.0k)221.0k

Cash From Operating Activities

(19.9m)(36.5m)(50.5m)(25.9m)(51.7m)68.1m
USDFY, 2017

Financial Leverage

-2.8 x
Show all financial metrics

Precision BioSciences Operating Metrics

FY, 2018

Discovery Projects

3

Pre-Clinical Phase Products

4
Show all operating metrics

Precision BioSciences Acquisitions / Subsidiaries

Company NameDateDeal Size
ELO Life Systems
ELO Life Systems Australia Pty. Ltd.

Precision BioSciences Revenue Breakdown

Embed Graph

Precision BioSciences revenue breakdown by business segment: 87.5% from Therapeutics and 12.5% from Food

Precision BioSciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Precision BioSciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Precision BioSciences Online and Social Media Presence

Embed Graph

Precision BioSciences News and Updates

Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

Precision Gains Access to Tiziana’s Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio Precision Gains Access to Tiziana’s Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio

Precision BioSciences Announces CEO Transition Plan

Begins Search for Next Chief Executive Officer Begins Search for Next Chief Executive Officer

Precision BioSciences to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day

DURHAM, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it will participate in the Guggenheim Healt…

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update

Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021

DURHAM, N.C., March 12, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year 2020 financial results and provide a business update on Thursday, March 18, 2021.

Precision BioSciences to Present at Upcoming Virtual Investor Conferences

DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced management will participate in the followin…
Show more

Precision BioSciences Blogs

Allogeneic CAR T cells with Deoxycytidine Kinase Knockdown Demonstrate Resistance to Fludarabine

Pires, M. et al. Journal for ImmunoTherapy of Cancer. 9,6 (2021). SITC 36th Annual Meeting. The post Allogeneic CAR T cells with Deoxycytidine Kinase Knockdown Demonstrate Resistance to Fludarabine appeared first on Precision BioSciences.

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion is Highly Active in Subjects with Relapsed/Refractory B-Cell Malignancies

Shah, B.D. et al. Blood. 138, 302 (2021). The post Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion is Highly Active in Subjects with Relapsed/Refractory B-Cell Malignancies appeared first on Precision BioSciences.

Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic ‘Off-the-Shelf’ CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL

Nitin, J. et al. Blood. 138, 650 (2021). The post Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic ‘Off-the-Shelf’ CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL appeared first on Precision BioSciences.

Precision BioSciences to Present at the 40th Annual J.P. Morgan Health Care Conference

DURHAM, N.C. --(BUSINESS WIRE)--Jan. 4, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that Michael Amoroso , Chief Executive The po…

Precision BioSciences Completes Spin-Out of Elo Life Systems

DURHAM, N.C. --(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with T…

Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021

Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021 Content Import Mon, 12/06/2021 - 16:49 Precision BioSciences to Host Virtual Webcast and Conference Call to R…
Show more

Precision BioSciences Frequently Asked Questions

  • When was Precision BioSciences founded?

    Precision BioSciences was founded in 2006.

  • Who are Precision BioSciences key executives?

    Precision BioSciences's key executives are Kevin Buehler, Cindy Atwell and Dario Scimeca.

  • How many employees does Precision BioSciences have?

    Precision BioSciences has 199 employees.

  • What is Precision BioSciences revenue?

    Latest Precision BioSciences annual revenue is $24.3 m.

  • What is Precision BioSciences revenue per employee?

    Latest Precision BioSciences revenue per employee is $122 k.

  • Who are Precision BioSciences competitors?

    Competitors of Precision BioSciences include Freeline, StrideBio and HotSpot Therapeutics.

  • Where are Precision BioSciences offices?

    Precision BioSciences has an office in Durham.

  • How many offices does Precision BioSciences have?

    Precision BioSciences has 1 office.